Clinical Trials Logo

Refractory Cytopenias clinical trials

View clinical trials related to Refractory Cytopenias.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00303472 Completed - Clinical trials for Myelodysplastic Syndromes

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.